Potentials of ribosomopathy gene as pharmaceutical targets for cancer treatment

doi: 10.1016/j.jpha.2023.10.001

• Mengxin Wang^a,b , 
• Stephen Vulcano^c , 
• Changlu Xu^d , 
• Renjian Xie^a,e , 
• Weijie Peng^a , 
• Jie Wang^f , 
• Qiaojun Liu^a,g , 
• Lee Jia^{h ,  ,}  , 
• Zhi Li^{d ,  ,}  , 
• Yumei Li^{a,g ,  ,} 

• a. Key Laboratory of Biomaterials and Biofabrication in Tissue Engineering of Jiangxi Province, Gannan Medical University, Ganzhou, Jiangxi, 341000, China;

• b. School of Rehabilitation Medicine, Gannan Medical University, Ganzhou, Jiangxi, 341000, China;

• c. Autoimmunity and Inflammation Program, HSS Research Institute, Hospital for Special Surgery New York, New York, NY, 10021, USA;

• d. Division of Oral and Systemic Health Sciences, School of Dentistry, University of California, Los Angeles, CA, 90095, USA;

• e. School of Medical Information Engineering, Gannan Medical University, Ganzhou, Jiangxi, 341000, China;

• f. Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, Institute for Liver Diseases of Anhui Medical University, School of Pharmacy, Anhui Medical University, Hefei, 230032, China;

• g. School of Basic Medicine, Gannan Medical University, Ganzhou, Jiangxi, 341000, China;

• h. Institute of Oceanography, Minjiang University, Fuzhou, 350108, China